Juventas CAR-T LBCL Launch Marks Second Indication

Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory large B-cell lymphoma (r/r LBCL) across multiple locations in China, marking the second indication for its self-developed CD19-targeted CAR-T therapy.

Regulatory & Commercial Milestone

Development & Approval Timeline

Product Profile & Mechanism

• Technology: Self-developed CD19-targeted chimeric antigen receptor (CAR) T-cell therapy
• Mechanism: Genetically engineered T-cells expressing CD19-binding CAR to eliminate malignant B-cells
• Manufacturing: Autologous cell therapy produced in Juventas’ GMP facilities
• Administration: Single intravenous infusion following lymphodepletion chemotherapy

Market Context & Competitive Landscape

Strategic Outlook & Commercial Implications

• Multi-Location Launch: Demonstrates robust commercial infrastructure and supply chain readiness
• Portfolio Expansion: Dual indications (B-ALL + LBCL) maximize manufacturing facility utilization
• Market Penetration: LBCL indication addresses larger patient population vs. B-ALL
• Revenue Impact: Analysts project ¥500-800 million peak sales from LBCL indication by 2028
• Pipeline Value: Validates platform technology for potential future CAR-T candidates in solid tumors

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Juventas’ commercial launch execution, market penetration, and revenue projections for inaticabtagene autoleucel. Actual results may differ due to manufacturing capacity, competitive dynamics, and reimbursement uncertainties.-Fineline Info & Tech